

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Buccal insulin for the management of type 1 diabetes

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Generex Biotechnology (buccal insulin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Children • Action for Sick Children • Afiya Trust • Age Concern & Help the Aged • Black and Ethnic Minority Diabetes Association (BEMDA) • Black Health Agency • Children with Diabetes • Children's Society • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Diabetes Research & Wellness Foundation • Diabetes UK • Equalities National Council • Insulin Dependent Diabetes Trust • Juvenile Diabetes Research Foundation • Muslim Council of Great Britain • Muslim Health Network • National Childbirth Trust • National Children's Bureau • National Parent Partnership Network • Network of Sikh Organisations • South Asian Health Foundation • Specialised Healthcare Alliance • Surya Foundation 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Commissioning Support Unit - Appraisals • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Medicines and Healthcare products Regulatory Agency (MHRA) • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Eli Lilly (insulin lispro, soluble insulin) • Novo Nordisk (soluble insulin, insulin aspart) • sanofi-aventis (soluble insulin, insulin glulisine) • Wockhardt (soluble insulin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Diabetes Foundation • Heart Disease and Diabetes Research Trust • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • WellChild <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Clinical Diabetologists • British Association for Services to the Elderly • British Geriatrics Society • British Society for Paediatric Endocrinology and Diabetes • Diabetes Monitoring Forum • National Diabetes Nurse Consultant Group • Primary Care Diabetes UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Milton Keynes PCT • Oldham PCT • Welsh Assembly Government 	<p>and Ethnicity</p> <ul style="list-style-type: none"> • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Evidence Review Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guidelines Centre • National Collaborating Centre for Women’s and Children’s Health <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.